RxSight reports Q3 adjusted EPS 0c, consensus (25c)

Reports Q3 revenue $35.3M, consensus $35.06M. “We are pleased to report another strong quarter driven by ongoing demand and enthusiasm for the RxSight (RXST) system,” said Dr. Ron Kurtz, Chief Executive Officer and President. “With 78 LDDs sold this quarter and sustained growth in LAL sales, we continue to see recognition of the transformative power of adjustability and the significant value it provides to both patients and doctors. We believe our third-quarter results position us for a strong finish to 2024 and for continued success in the years to come.”